恶性肿瘤患者血清β2-MG检测的临床分析

探讨血清β2-MG定量检测对恶性肿瘤的诊断价值。用免疫透射比浊法检测1800例恶性肿瘤患者、120例良性肿瘤患者和100名正常人（对照组）血清β2-MG水平。结果表明,各恶性肿瘤组与对照组血清β2-MG相比,差异均有统计学意义（P〈0.05）;良性肿瘤组与对照组血清β2-MG相比,差异无统计学意义（P〉0.05）。乳腺癌组与良性肿瘤组的血清β2-MG相比,差异无统计学意义（P〉0.05）;肾癌、前列腺癌、膀胱癌、卵巢癌等恶性肿瘤组与良性肿瘤组的血清β2-MG相比,差异均有统计学意义（P〈0.05）。除乳腺癌外,血清β2-MG有助于鉴别肾、前列腺、膀胱和卵巢等良恶性肿瘤。

Clinical Significance of Detection of β2-microglobulinin Patients with Malignant Tumor

To explore the clinical value of detection of serum level of β2-MG in malignant tumor,the serum levels of β2-MG in 1800 patients with malignant tumor,120 patients with benign tumor and 100 healthy controls were measured by a transmission turbidmetic immunoassay.The results showed that the serum levels of β2-MG in patients with malignant tumor were significantly different with that of healthy controls(P<0.05),and there was no significant difference between patients with benign tumor and healthy controls(P>0.05).The serum β2-MG levels in patient with mammary cancer have no statistics significance compared with patients with benign tumor(P>0.05).The serum β2-MG levels in patients with kidney cancer,prostate cancer and ovarian cancer were significant different compared with patients with benign tumor(P<0.05).The serum β2-MG level may be helpful in identification of patients with benign or malignant tumor except mammary cancer.